Olympian Clara Hughes on menopause and psychedelic therapy: 'I had to go hard' - Toronto Star

St. Joseph’s Healthcare Hamilton is expanding research into the potential medical use of psychedelics following two $1-million philanthropic investments in its new Centre for Health Innovation and Research in Psychedelics (CHIRP). The $2 million in combined funding comes from Hamilton philanthropist Teresa Cascioli and The Juravinski Foundation and represents the first major philanthropic investments in the centre, which was launched last fall.

With sadness and gratitude for a wonderful life, we announce the passing of Clara (Claire) Hunston at 93 years young. Born January 5, 1933, in Lowe Farm, Manitoba, Claire was the seventh of ten children (the youngest of four daughters) born to Abram and Anna Wiebe. Claire cherished her childhood on the family farm in southern Manitoba, where her family was deeply rooted in the Mennonite faith. Curious, musical, and always interested in people, she followed opportunities wherever they led. She went on to attend teacher’s college, then university in Winnipeg, before teaching for a year in Germany and four years in the Arctic. She met her husband, Ken Hunston, in Iqaluit. They eventually married in Port Alberni, then moved on to the remote logging community of Kingcome Inlet, which she loved. They later settled in Campbell River, where their daughter, Jennifer, was born.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.